KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Capital Expenditures (2017 - 2025)

Twist Bioscience (TWST) has disclosed Capital Expenditures for 7 consecutive years, with -$914000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Capital Expenditures rose 98.84% to -$914000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $772000.0, a 87.74% decrease, with the full-year FY2025 number at $2.4 million, down 52.56% from a year prior.
  • Capital Expenditures was -$914000.0 for Q3 2023 at Twist Bioscience, up from -$19.2 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $40.6 million in Q2 2022 to a low of -$79.1 million in Q3 2022.
  • A 5-year average of $3.0 million and a median of $3.9 million in 2019 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 722.26% in 2019, then crashed 1077.85% in 2022.
  • Twist Bioscience's Capital Expenditures stood at $2.1 million in 2019, then soared by 76.34% to $3.6 million in 2020, then skyrocketed by 252.25% to $12.8 million in 2021, then decreased by 7.5% to $11.8 million in 2022, then tumbled by 107.73% to -$914000.0 in 2023.
  • Per Business Quant, the three most recent readings for TWST's Capital Expenditures are -$914000.0 (Q3 2023), -$19.2 million (Q2 2023), and $9.1 million (Q1 2023).